These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 19694767)

  • 1. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation.
    Michalopoulos A; Virtzili S; Rafailidis P; Chalevelakis G; Damala M; Falagas ME
    Clin Microbiol Infect; 2010 Feb; 16(2):184-6. PubMed ID: 19694767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
    Pontikis K; Karaiskos I; Bastani S; Dimopoulos G; Kalogirou M; Katsiari M; Oikonomou A; Poulakou G; Roilides E; Giamarellou H
    Int J Antimicrob Agents; 2014 Jan; 43(1):52-9. PubMed ID: 24183799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study.
    Michalopoulos A; Fotakis D; Virtzili S; Vletsas C; Raftopoulou S; Mastora Z; Falagas ME
    Respir Med; 2008 Mar; 102(3):407-12. PubMed ID: 18060758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cluster of bloodstream infections caused by KPC-2 carbapenemase-producing Klebsiella pneumoniae in Manhattan.
    Nadkarni AS; Schliep T; Khan L; Zeana CB
    Am J Infect Control; 2009 Mar; 37(2):121-6. PubMed ID: 19249638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of carbapenem resistance on the outcome of patients' hospital-acquired bacteraemia caused by Klebsiella pneumoniae.
    Hussein K; Raz-Pasteur A; Finkelstein R; Neuberger A; Shachor-Meyouhas Y; Oren I; Kassis I
    J Hosp Infect; 2013 Apr; 83(4):307-13. PubMed ID: 23313086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbapenem-resistant Klebsiella pneumoniae endocarditis in a young adult. Successful treatment with gentamicin and colistin.
    Benenson S; Navon-Venezia S; Carmeli Y; Adler A; Strahilevitz J; Moses AE; Block C
    Int J Infect Dis; 2009 Sep; 13(5):e295-8. PubMed ID: 19329345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options.
    Kontopidou F; Giamarellou H; Katerelos P; Maragos A; Kioumis I; Trikka-Graphakos E; Valakis C; Maltezou HC;
    Clin Microbiol Infect; 2014 Feb; 20(2):O117-23. PubMed ID: 23992130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K; Reshedko G; Orasan R; Sanchez M; Teras J; Babinchak T; Dukart G; Cooper A; Dartois N; Gandjini H; Orrico R; Ellis-Grosse E;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections.
    Ben-David D; Kordevani R; Keller N; Tal I; Marzel A; Gal-Mor O; Maor Y; Rahav G
    Clin Microbiol Infect; 2012 Jan; 18(1):54-60. PubMed ID: 21722257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
    Michalopoulos A; Kasiakou SK; Mastora Z; Rellos K; Kapaskelis AM; Falagas ME
    Crit Care; 2005 Feb; 9(1):R53-9. PubMed ID: 15693967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study.
    Markou N; Markantonis SL; Dimitrakis E; Panidis D; Boutzouka E; Karatzas S; Rafailidis P; Apostolakos H; Baltopoulos G
    Clin Ther; 2008 Jan; 30(1):143-51. PubMed ID: 18343250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nosocomial liver abscess caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae.
    Lin JC; Siu LK; Fung CP; Yeh KM; Chang FY
    J Clin Microbiol; 2007 Jan; 45(1):266-9. PubMed ID: 17093025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for developing clinical infection with carbapenem-resistant Klebsiella pneumoniae in hospital patients initially only colonized with carbapenem-resistant K pneumoniae.
    Borer A; Saidel-Odes L; Eskira S; Nativ R; Riesenberg K; Livshiz-Riven I; Schlaeffer F; Sherf M; Peled N
    Am J Infect Control; 2012 Jun; 40(5):421-5. PubMed ID: 21906844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes.
    Nguyen M; Eschenauer GA; Bryan M; O'Neil K; Furuya EY; Della-Latta P; Kubin CJ
    Diagn Microbiol Infect Dis; 2010 Jun; 67(2):180-4. PubMed ID: 20356699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection.
    Hirsch EB; Tam VH
    J Antimicrob Chemother; 2010 Jun; 65(6):1119-25. PubMed ID: 20378670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for the acquisition of nosocomial infection with carbapenem-resistant Klebsiella pneumoniae.
    Wu D; Cai J; Liu J
    South Med J; 2011 Feb; 104(2):106-10. PubMed ID: 21258230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece).
    Maltezou HC; Giakkoupi P; Maragos A; Bolikas M; Raftopoulos V; Papahatzaki H; Vrouhos G; Liakou V; Vatopoulos AC
    J Infect; 2009 Mar; 58(3):213-9. PubMed ID: 19246099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ongoing epidemic of blaVIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey.
    Psichogiou M; Tassios PT; Avlamis A; Stefanou I; Kosmidis C; Platsouka E; Paniara O; Xanthaki A; Toutouza M; Daikos GL; Tzouvelekis LS
    J Antimicrob Chemother; 2008 Jan; 61(1):59-63. PubMed ID: 17999975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endoscopy-associated transmission of carbapenem-resistant Klebsiella pneumoniae producing KPC-2 beta-lactamase.
    Naas T; Cuzon G; Babics A; Fortineau N; Boytchev I; Gayral F; Nordmann P
    J Antimicrob Chemother; 2010 Jun; 65(6):1305-6. PubMed ID: 20382724
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.